Disease relapse following an allogeneic transplant remains a major cause of treatment failure, often with a poor outcome. Second allogeneic transplant procedures have been associated with high TRM, especially with myeloablative conditioning. We hypothesized that the use of reduced-intensity conditioning (RIC) would decrease the TRM. We performed a retrospective national multicentre analysis of 71 patients receiving a second allogeneic transplant using RIC after disease relapse following an initial allogeneic transplant. The majority of patients had leukaemia/myelodysplasia (MDS) (N ¼ 57), nine had lymphoproliferative disorders, two had myeloma and three had myeloproliferative diseases. A total of 25% of patients had unrelated donors. The median follow-up was 906 days from the second allograft. The predicted overall survival (OS) and TRM at 2 years were 28 and 27%, respectively. TRM was significantly lower in those who relapsed late (411 months) following the first transplant (2 years: 17 vs 38% in early relapses; P ¼ 0.03). Two factors were significantly associated with a better survival: late relapse (P ¼ 0.014) and chronic GVHD following the second transplant (P ¼ 0.014). These data support our hypothesis that the second RIC allograft results in a lower TRM than using MA. A proportion of patients achieved a sustained remission even when relapsing after a previous MA transplant.
Introduction
Disease relapse following an allogeneic transplant procedure remains a significant cause of treatment failure. Depending on the disease type and status at the time of the procedure, a relapse risk of up to 70% may be seen. 1, 2 In most cases, the optimal management of relapsed patients is unclear, and with the exception of CML, the prognosis in most patients has been poor. 3 Most studies agree that the conventional chemotherapy alone in this setting is usually insufficient to obtain the long-term disease control. [4] [5] [6] The use of donor leukocyte infusions (DLIs) has been associated with improved outcomes and long-term disease-free survival (DFS); [7] [8] [9] however, successful outcomes are limited to certain diseases and in many cases, the responses to DLI are unpredictable. 10, 11 The use of a second allogeneic procedure, using MA conditioning, has been reported to be associated with improved DFS compared with other interventions; however, this has come at the price of greatly increased rates of TRM. 12 A strategy for reducing TRM that has been successfully employed over the last decade is the use of nonmyeloablative or reduced-intensity conditioning (RIC) regimens. These protocols exploit the graft-versus-malignancy effect as an immunological method of ongoing disease control. [13] [14] [15] They have also been associated with a low TRM in patients who have undergone a previous autologous transplant. 16 There are, however, few studies published considering the use of an RIC regimen as preparation for a second allogeneic transplant following the relapse of the original disease. 17, 18 We hypothesized that the use of RIC could reduce the TRM associated with a second allogenic transplant and result in survival in a proportion of patients. The aim of this retrospective descriptive study was to analyse the outcome in UK patients receiving a reduced-intensity allograft for disease relapse following the first allogeneic procedure and identify factors predicting for the improved outcome. This study included patients transplanted for all types of malignant diseases and those transplanted using an unrelated donor.
Patients and methods

Data collection
Patients fulfilling the requirements for this study were identified from the database held by the British Society for Blood and Marrow Transplantation registry in London, UK. Data are reported at fixed time points to the Society in the form of Med A and B forms (standardized international forms recording 'minimal essential data'). A total of 71 patients from 21 centres were identified. Supplementary data were applied for from all centres, and obtained from all but one centre (one patient).
Patients and inclusion criteria
Criteria for inclusion were (1) a transplant at the UK centre, (2) patients receiving a second infusion of haematopoietic stem cells from a related or unrelated donor for relapse of a haematological malignancy following a first allogeneic transplant and (3) conditioning for the second procedure was reduced intensity (Table 1) . Patients who received second haematopoietic cell infusions for primary or secondary graft failure were excluded.
The protocols used were approved by the individual institutional review boards of all of the contributing hospitals. The appropriate ethical permission was obtained and all patients and donors signed informed consent before transplant/donation.
Statistical analyses
Relationships between categorical variables were analysed by Fisher's exact test. Overall survival (OS) was calculated by Kaplan-Meier analysis. Univariate analysis of OS was performed using the log-rank test, and multivariate analysis by Cox regression. Cumulative incidence of TRM was calculated by competing risks regression, with death from relapse as the competing risk. Relapse rate was calculated as a cumulative incidence by competing risks regression, with transplant-related death as the competing risk.
Statistics tests were performed using Stata (StataCorp, TX, USA; URL: http://www.stata.com), with competing risks calculated using 'stcompet' (Enzo Coviello, Italy; May Boggess, StataCorp); and using R (R Development Core Team (2006) . R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http:// www.R-project.org), with competing risks calculated using the package 'cmprsk' (RJ Gray).
Results
Patient and transplant characteristics
A total of 71 patients were included in the study. Patient, disease and transplant characteristics at the first and second transplants are presented in Table 1 . Transplants were performed between April 1992 and July 2006. The first allograft was with MA in 47 (68%) and RIC in 23 (33%). Abbreviations: MDS ¼ myelodysplasia; MPD ¼ myeloproliferative disease; MM ¼ multiple myeloma. a T-cell depletion was in vivo using alemtuzumab.
At the second allograft, 89% of the conditioning regimens were fludarabine containing ( Table 1 ). The majority of the transplants were performed in patients with leukaemia and MDS (57); however, a transplant was performed for a lymphoproliferative disease in nine patients, myeloma in two patients and myeloproliferative disease (MPD) in three patients. The median age of the patients at the first and second transplants was 39 (range: 8-69 years) and 43 years, respectively. The donor was an identical sibling, other related or unrelated in 50, 18 and three patients at the first transplant; and 49, 18 and four patients at the second transplant, respectively. Of the 14 patients who had a different donor at the second transplant, six had a different identical sibling donor, six had a different unrelated donor, one had another related donor (following an identical sibling) and one had an unrelated donor (following a syngeneic donor). The median time to relapse following the first transplant was 11 months (2 months to 12.3 years).
The median time between the two transplants was 1.4 years (2 months to 12.6 years) and the median time from relapse to the second transplant was 3 months (o1 -5.5 months).
The majority of patients received one or more interventions before the second transplant: chemotherapy (±monoclonal antibodies) in 27 and DLI (±chemotherapy) in 24 patients.
Engraftment
A total of 1.5% (1/66) of patients had primary graft failure following the second allograft (defined as a failure to achieve a neutrophil count of 0.5 Â 10 9 /l in those surviving at least 28 days after the transplant). The patient with primary graft failure died on day 68 of progressive disease.
GVHD
All patients who achieved neutrophil engraftment were considered eligible for analysis. The incidence of grade II-IV acute GVHD (aGVHD) following the first and second transplants was 8/69 (11%) and 17/65 (26%), respectively. Chronic GVHD (cGVHD) was present in 13/68 (19%; extensive in two patients) patients following the first allograft and 20/48 (42%; extensive in seven patients) following the second procedure. The incidence of GVHD was not significantly different dependent on the use of T-cell depletion, donor type or the source of stem cells for either transplant. Furthermore, the incidence of aGVHD or cGVHD was not significantly different following the second transplant compared to the first transplant. This finding also applied to those transplants where a different donor was used.
TRM TRM following the second transplant was 15 and 23% at day 100 and 1 year, respectively (Figure 1 ). The only significant factor affecting TRM was early relapse. The risk of TRM was significantly higher in those who had relapsed early (o11 months) following the first transplant compared with those with late relapse (2 years: 38 vs 17%; P ¼ 0.03; Figure 2 ). There was no significant difference dependent on age, type of conditioning for the first allograft, use of BM or PBSC (either allograft), disease type, disease status at the second allograft or donor type.
In total, 47 patients have died. The causes of death are relapse (29, 60%), GVHD (four, 9%), infection (12, 27%) or other (two, 4%).
Relapse
The median time to relapse following the second allograft was 134 days (7-1692) and the cumulative incidence was 48 and 56% at 1 and 2 years, respectively (Figure 1) . At 1 year, the relapse risk was 18% in the lymphoproliferative disorders, 62% in AML, 50% in ALL, 57% in CML, Transplant mortality rate and relapse mortality rate 21% in MDS and one of two in patients with myeloma. There was a significantly lower relapse risk at 2 years in those who were older than the median age (43 years) than in younger patients (47% at 2 years compared to 66%; P ¼ 0.04); however, this was not significant in multivariate analysis. The probability of disease relapse at 2 years was 63% in those without cGVHD and 44% in those with cGVHD (P ¼ 0.15).
Survival
The median follow-up of the survivors is 906 days (3 months to 7.4 years). The OS in the cohort was 42 and 27% at 1 and 2 years, respectively (Figure 3) , with the appearance of a plateau thereafter. The EFS was 33 and 22% at the same time points. There was a difference in outcome dependent on disease subtype (Figure 4a) . At 2 years, the survival was 89% in lymphoproliferative disorders, AML 18%, ALL 22%, MDS 17%, 0% CML and myeloproliferative disease, and one of the two patients with myeloma was alive. The most significant determinant of the outcome was the time to relapse following the first transplant (above or below median, 11 months) with an OS of 31% at 2 years in those who relapsed late compared to 23% in those relapsed early (P ¼ 0.014; Figure 4b ). There was a trend to improved survival in those who had an RIC compared with MA conditioning for the first transplant (P ¼ 0.08), and in those who achieved full donor chimerism compared with the mixed chimerism (P ¼ 0.05). There was no significant difference dependent on age, use of BM or PBSC or T-cell depletion (either allograft), disease status at the first or second allograft, use of an alternate donor or donor type. Although aGVHD at any time did not impact significantly on OS in the cohort as a whole, there was a significant survival advantage to developing aGVHD following the second allograft in those patients who relapsed before 11 months (2 years: 38% with aGVHD compared to 0% without, P ¼ 0.003) (Figure 4c) . Patients who developed cGVHD following the second allograft had a significant survival advantage compared to those that did not (2 years: 54% compared to 29%; P ¼ 0.014; Figure 4d ).
Discussion
This is the largest study to date of patients receiving an RIC transplant for disease that relapses following an initial allograft. In addition, it is the first to report such transplants for diseases other than leukaemia and using donors other than HLA-identical siblings. These results show that using this approach, a proportion of patients who relapse can achieve long-term DFS. Survival was particularly good in patients with a late relapse (after 1 year) as these patients have a low TRM, and in those who develop GVHD. In some diseases, such as ALL, an RIC allograft appears to be superior to other forms of salvage treatment.
There is a large published experience of the use of second MA allografts to treat disease relapse following the first transplant. 2, 12, 19, 20 Historically, such an approach was complicated by high rates of TRM and even in recent studies, the TRM is reported to be between 28 and 46% (at 3-5 years). 2, 19, 21 To reduce this high TRM, the second transplants using RIC have been increasingly performed, although few reports describing such an approach have been published, 17, 18, 21 and in most of these studies, numbers are small making interpretation of the data difficult. In our study of 71 patients, TRM was low (24% at 1 year) compared with the second MA transplants, particularly in those patients who relapsed more than 1 year after transplant (where the TRM was 13% at 1 year), which is comparable to that expected after the first allogeneic transplant.
In comparison, a large study of 279 patients from the International Bone Marrow Transplant Registry 21 reported the outcomes of second allografts including 45 patients who had an RIC. In this study, the overall TRM was 26 and 30% at 1 and 5 years, respectively with no specific comment on the effect of RIC as the second transplant; however, unlike our report, this study was confined to sibling transplants. Two previous small studies have reported a low TRM using RIC. A study by Pawson et al. 17 reported the outcomes in 14 patients treated with a fludarabine and high-dose cytarabine-containing conditioning regimen for relapse following a sibling allograft. This approach was well tolerated with no treatment-related deaths having occurred at the time of the report. A similar approach is reported in nine patients with high-risk AML/MDS who relapsed within a year of an MA transplant. 18 Again, there were no deaths owing to TRM. In both studies, CRs were reported with a proportion of patients surviving long term.
In the current study, the OS was significantly better in the subgroup of patients who relapsed late compared to those relapsing early. This difference was noted after 11 months and was primarily owing to a low TRM. There was no significant difference in the outcome when we compared those who relapsed before or after 6 months. % surviving Figure 3 Overall survival in the whole group.
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The observed impact of the time to relapse on outcome is consistent with other reports, many suggesting that this factor may be the most important in determining the outcome. The International Bone Marrow Transplant Registry 21 reported the outcomes in 279 patients with acute leukaemia who relapsed following an HLA-matched sibling allograft and went on to receive the second allograft using myeloablative or RIC. The probability of OS was 41 and 28% at 1 and 5 years, respectively. Those who relapsed less than 6 months after the first allograft had a relative risk of mortality of 3.47. A European Society for Blood and Marrow Transplantation (EBMT) study 2 presented the outcome data on 170 patients with relapsed leukaemia following allograft, who had the second transplant as salvage. Once again, the time to relapse was a significant factor determining outcome, with those relapsing 4292 days having a relative risk (RR) of mortality of 0.5. Several other studies have found this factor to be significant, correlating a worse OS with relapse either o 1 year 19, 22 o136 days 4 or o6 months. 23 These findings suggest that a major consideration when deciding on salvage treatment for a patient who relapses should be the time to relapse occurrence. With this in mind, we nevertheless observed a probability of OS at 2 years of 23% in those who relapsed before 1 year after the first allograft, suggesting that even within this unfavourable group, there may be long-term survivors.
In this cohort, the presence of cGVHD was significantly associated with an improved OS, as was the presence of full donor chimerism, although these were independent factors. In addition, in patients relapsing o11 months after the first transplant, we also observed a significant survival advantage in those who developed aGVHD, in fact comparable to the OS at 2 years in patients who relapsed late. Owing to the relatively low incidence of GVHD, we were unable to identify any significant factors predicting for this complication. Larger studies may help to uncover these, in particular to assess the impact of T-cell depletion in this setting. The positive association of GVHD and survival has previously been reported in this setting 2, 19 in some cases associated with a decrease in the relapse risk. In this study, although the relapse risk was decreased in patients with cGVHD, this was not statistically significant. It is possible that this is owing to the low numbers and relatively short follow-up in some patients. Alternately, the protective effect of GVHD on disease relapse may differ Second allogeneic transplants using RIC for relapse BE Shaw et al between diseases and thus the impact was lost in this heterogenous cohort.
In our study, we found no other factor to have a significant impact on OS, although there was a trend for better survival in those who received RIC for their first transplant. Other studies have found factors such as age o 20 years, 19, 21 disease status at second transplant, 2 use of TBI, 2 absence of aGVHD 19 and use of a female donor 19 to be important; however, these factors are not consistent between studies. A possible explanation for this is the difference in study cohorts with regards to factors such as age, disease type and conditioning regimen. In our study, few children were included (15% under 20 years). Although older patients in our study were less likely to relapse, this was not significant in multivariate analysis, and is likely to reflect the relapse risk for the underlying disease. In addition, when using RIC, many studies have reported no significant differences in outcome based on age, suggesting that this approach need not be limited to younger patients. [24] [25] [26] The inclusion of patients with lymphoproliferative diseases meant that many of the patients with a favourable outcome were not in a CR at the second transplant.
The cohort of patients with acute leukaemia in this study is sufficiently large to allow the cautious conclusions to be drawn, particularly in the context of results from previous similar studies. Data from the International Bone Marrow Transplant Registry, mainly using MA for second transplants, showed an OS at 3 years of 27% in AML and 30% in ALL, 21 whereas the EBMT reported an OS of 38% in AML and 25% in ALL at the same time point. 2 In AML, these results approximate to those achieved by using DLI, with survival at 2 years reported at between 19-55%. 5, [27] [28] [29] [30] As in the second allografts, the time to relapse after the first transplant is a significant determinant of the response to DLI. 4, 5 In addition, there is a strong suggestion that the use of chemotherapy before DLI results in better outcomes. 5, 31 A major challenge to the field is when to recommend DLI ( ± chemotherapy), when a second allograft or, indeed, whether the two approaches can be combined to achieve superior outcomes. The lack of consistency in the salvage approach in this study precludes firm conclusions.
In contrast, in patients with ALL, the outcome after the second allograft appears to be superior to that following DLI. The long-term survivors after DLI are seldom reported in the literature with larger studies reporting OS of 0-13% at 3 years. [32] [33] [34] On the basis of these observations, we suggest that in ALL, the second allograft should be considered the treatment of choice, if a salvage strategy is offered.
The best outcome was seen in patients with lymphoproliferative disorders. Sustained remissions have been reported following DLI in indolent lymphoproliferative diseases, whereas the results are poor in those with aggressive disease. 9 Although the numbers in this study are small, the results suggest at least an equivalent response to the second allograft overall, justified by minimal toxicity.
Interestingly, in this study, we found no significant difference in the incidence of OS, relapse or TRM between patients receiving transplants from an unrelated or a sibling donor. In addition, as has been previously reported, 21 we found no significant difference in the incidence of GVHD or OS dependent on whether the same or a different donor was used. Therefore, there seems no need to delay the second procedure if the original donor remains available. This study has significant limitations. Owing to the retrospective nature of the study, it is probable that the significant inherent selection biases exist. It is possible that patients selected for the second allograft may represent a favourable subset of patients who relapse. A prospective study, which describes the outcome of all relapsed patients is required to delineate the role of this intervention.
In conclusion, we have confirmed our hypothesis that the use of RIC for the second allograft for disease relapse following the first procedure results in a low and acceptable TRM. In addition, we have shown that in a proportion of patients, the long-term survival is possible, and therefore this approach may be preferable to the second MA transplant particularly in those patients with a late relapse.
